- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Intravitreal anti-VEGF injections increase adverse events in diabetics: JAMA
Among patients with diabetes, intravitreal anti-VEGF injections were independently linked to a greater risk of systemic adverse effects, says an article published in JAMA Ophthalmology.
Currently, the majority of treatment for diabetic retinopathy (DR) is anti-vascular endothelial growth factor (VEGF) medications. Although effective, evidence on their systemic safety are still lacking, especially in patient populations at high risk. In order to investigate the systemic safety of intravitreal anti-VEGF medicines among patients with diabetes, Sidra Zafar and colleagues undertook this study.
This study examined the Corporate Data Warehouse, a sizable patient database housed inside the US Veteran Health Affairs, retrospectively and longitudinally. Between January 1, 2011, and December 31, 2012, all patients with type 2 diabetes who were 18 years of age or older and seen at any Veterans Affairs medical facility in the US were recorded. On incident systemic adverse events that occurred in this patient group between January 1, 2013, and December 31, 2017, data were then retrieved. Both those with diabetes who had anti-VEGF injections and those who did not were included. Patients who got an intravitreal injection between January 1, 2011, and December 31, 2012, as well as those with a history of past systemic adverse effects, were excluded. Data were examined between October 2023 and March of 2019.
At 1-, 3-, and 5-year follow-up, the percentage of patients who experienced any incident systemic adverse event, acute myocardial infarction, cardiovascular disease, or renal disease.
The key findings of this study were:
1. Type 2 diabetes patients numbered 1 731 782 in total. 476 013 (27.5%) of patients had DR, while 14 022 (0.8%) got anti-VEGF injections.
2. Between 2013 and 2017, 321 940 individuals with type 2 diabetes (18.6%) experienced systemic adverse events.
3. In the injection group, the cumulative incidence of any systemic adverse event over the course of five years was 37.0% (5187/14 022) compared to 18.4% (316 753/1 717 760) in the noninjection group (P .001).
4. When taking into account factors such as age, race, sex, ethnicity, smoking, the severity of DR, the Deyo-Charlson Comorbidity Index score, the mean HbA1c, the total number of injections, and statin use, anti-VEGF injections were found to be independently related with a greater risk of experiencing any type of systemic adverse event.
Reference:
Zafar, S., Walder, A., Virani, S., Biggerstaff, K., Orengo-Nania, S., Chang, J., & Channa, R. (2023). Systemic Adverse Events Among Patients With Diabetes Treated With Intravitreal Anti–Vascular Endothelial Growth Factor Injections. In JAMA Ophthalmology. American Medical Association (AMA). https://doi.org/10.1001/jamaophthalmol.2023.2098
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751